 |
 |
|||||||||||||||
 |
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
|
Intravenous Administration in Combination with Paclitaxel and Carboplatin In July 2009, Oncolytics announced that it had completed patient enrolment in a Phase II clinical trial using intravenous administration of REOLYSIN in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers. This trial is a 14-patient, single arm, open-label, dose-targeted, non-randomized, multi-centre trial of REOLYSIN® given intravenously in combination with a standard dosage of paclitaxel and carboplatin. Eligible patients include those with advanced or metastatic head and neck cancer that are refractory to standard therapy or for which no curative standard therapy exists. The primary objective of the Phase II trial is to measure tumour responses and duration of response, and to describe any evidence of antitumour activity. The secondary objective is to determine the safety and tolerability of REOLYSIN® when administered in combination with paclitaxel and carboplatin to patients with advanced or metastatic head and neck cancer. See related press releases and documents: June 7, 2010 - Oncolytics Biotech(R) Inc. Collaborators Present Positive Updated U.K. Phase I/II Trial Results in Advanced Solid Cancers with a Focus on the Head and Neck at the ASCO Annual Meeting May 21, 2010 - Oncolytics Biotech® Inc. Announces Reovirus Research to be Presented at ASCO Annual Meeting November 17, 2009 - Oncolytics Biotech® Inc. Collaborators Present Positive Phase I/II Trial Results in Advanced Solid Cancers with a Focus on the Head and Neck at the AACR-NCI-EORTC Meeting July 2, 2009 - Oncolytics Biotech® Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN® and Paclitaxel/Carboplatin Head and Neck Cancer Trial March 20, 2009 - Oncolytics Biotech® Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN® and Paclitaxel/Carboplatin Trial November 3, 2008 - Oncolytics Biotech Inc. Collaborators Present Positive Phase I/II Combination REOLYSIN® and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting
June 5, 2008 - Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II Clinical Trial Investigating REOLYSIN® in Combination with Paclitaxel and Carboplatin |
|
|||||||||||
 |
|
 |